Sun Pharma is lined up to copy 4 of the blockbuster drugs on this tracker, which earned $33.4B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Sun Pharma's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Pomalyst | Bristol Myers Squibb | Generic | 2026 | Approved Aug 2026 | $2.7B |
| Jakafi | Incyte | Generic | 2028 | In litigation | $3.1B |
| Ozempic | Novo Nordisk | Generic | 2032 | Settled, terms confidential | ≈$19.3B |
| Rinvoq | AbbVie | Generic | 2037 | Settled Sep 2025 | $8.3B |
Company facts: Stock Analysis. Each drug page lists sources for these entries. Brand sales show the size of the market, not Sun Pharma's share of it.